First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies.
Saved in:
| Title: | First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies. |
|---|---|
| Authors: | Mahadevan, Daruka1 (AUTHOR) mahadevand@uthscsa.edu, Barve, Minal2 (AUTHOR), Mahalingam, Devalingam3 (AUTHOR), Parekh, Jay1 (AUTHOR), Kurman, Michael4 (AUTHOR), Strauss, James4 (AUTHOR), Tremaine, Larry4 (AUTHOR), Hromas, Robert1,4 (AUTHOR), Sills, Joshua4 (AUTHOR), McCulloch, John4 (AUTHOR), Harkey, John4 (AUTHOR), Suberg, Stacy4 (AUTHOR), Zimmerman, Lisa4 (AUTHOR), Zheng, Guangrong5 (AUTHOR), Zhou, Daohong1 (AUTHOR) |
| Source: | Journal of Hematology & Oncology. 11/12/2025, Vol. 18 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
